Disclosed is a vaccine which is safe and effective on Nipah virus infection. Also disclosed is a vector for use in the production of the vaccine. Further disclosed is a bivalent vaccine which has an excellent protective effect on a measles and Nipah virus infection and is free of complications upon inoculation. Specifically disclosed is a recombinant measles virus produced by inserting a gene encoding a protein involved in the protection against onset of Nipah virus infection into a measles virus genome. The protein involved in the protection against onset of Nipah virus infection is preferably protein-G or protein-F which is a membrane protein. Also specifically disclosed are a bivalent vaccine against measles and Nipah virus infection, which comprises the recombinant measles virus. Further specifically disclosed is an anti-serum produced from a body fluid collected from an animal infected by the recombinant measles virus. Still further specifically disclosed is a method for producing a vaccine against Nipah virus infection, which is characterized by using a measles virus as a vaccine vector.